News and Media

Tchaikapharma’s product portfolio was presented at the 6th congress of the Society of Cardiologists of Kosovo under the auspices of the European Society of Cardiology. Тhe company’s top products Tamaira, Co-Telsart, Amariton and Rosta were of particular interest as the preferred choice of the cardiologists in the country. This is one of the reasons why there has been a steady growth of Tchaikapharma’s sales in Kosovo in recent years.

The pandemic has caused problems in the forefront of predictability and access to medicines in the country. It was difficult to supply the basic (active) substances for pharmaceutical production, and a slight increase in the production of drugs.

In this context, even before the first global lockdown, the team of Tchaikapharma has prepared a stategy for action in the unprecedented situation, by defining three main challenges.

The full article is available here in Bulgarian.

The first humanitarian aid from Pleven is already on its way to the twin city of Nikolayev, expected to arrive tomorrow at noon.

The main donation consists of antiviral preparations, sleeping bags, external batteries for charging mobile phones, backpacks, lanterns – these were the requests of the local government in Nikolaev. The medicines were provided by Tchaikapharma High Quality Medicines through the Municipality of Pleven, the rest of the humanitarian aid was purchased from the financial donations of dozens of Pleven residents who supported the campaign.

2021 was a very successful year for the manufacturing facilities of Tchaikapharma High Quality Medicines in Plovdiv and Varna. Numerous improvements related to the modernization of the manufactiring process were introduced at the company’s plant in Plovdiv:

– a Production Permit was obtained for a new granulation room in the tablet manufacturing facility, doubling the capacity;

– additional warehouses for shaped parts were built;

– a capsule filling machine for solid capsules was purchased and installed;

– a Manufacturing Permit was obtained to include a new manufacturing activity – production of non-sterile products – hard capsules;

– a roller-compactor for dry granulation has been purchased and installed;

– new serialization equipment with Temper Evident module was purchased and installed on packaging line 4;

– a new high-performance liquid chromatography apparatus and a new stability monitoring chamber were purchased for the Quality Control Department.

In 2021, the manufacturing of sterile antibiotics from the group of cephalosporins, has increased manifold at the plant of Tchaikapharma in Varna.

The Company reports about growth in sales of antibiotics and respiratory drugs

Tchaikapharma High Quality Medicines Inc. reports revenue growth and profit more than doubling by the end of 2021.  The company’s net profit at the end of the last quarter for 2021 amounted to BGN 1,667 million compared to BGN 604 thousand at the end of 2020, an increase of 176%.

The strongest growth in 2021 was reported in sales of antibiotics and respiratory medicines, given the prevalence of COVID-19, to BGN 7,325 million compared to BGN 4,42 million in the previous year, or by 65,72% (BGN 2,9 million). There was also growth in sales of the company’s drugs for the nervous system, as well as for the digestive system and metabolism, oncology and musculoskeletal system and connective tissue.

In the last year, Tchaikapharma’s shares rose by 9.5% and its market capitalisation reached BGN 1.1 billion.

The full article is available here in Bulgarian.